BNP Paribas Financial Markets Increases Stake in Fractyl Health, Inc. (NASDAQ:GUTS)

BNP Paribas Financial Markets boosted its stake in Fractyl Health, Inc. (NASDAQ:GUTS) by 54.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 21,072 shares of the company’s stock after buying an additional 7,397 shares during the period. BNP Paribas Financial Markets’ holdings in Fractyl Health were worth $53,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of GUTS. Massachusetts Financial Services Co. MA lifted its stake in shares of Fractyl Health by 4.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock valued at $2,646,000 after purchasing an additional 49,289 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Fractyl Health by 56.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company’s stock valued at $204,000 after buying an additional 29,262 shares during the period. Beta Wealth Group Inc. bought a new stake in shares of Fractyl Health during the 3rd quarter valued at $44,000. Renaissance Technologies LLC purchased a new stake in shares of Fractyl Health in the 2nd quarter worth about $61,000. Finally, SG Americas Securities LLC bought a new position in shares of Fractyl Health in the 3rd quarter worth about $33,000.

Insiders Place Their Bets

In other Fractyl Health news, insider Jay David Caplan sold 64,197 shares of Fractyl Health stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $2.47, for a total value of $158,566.59. Following the completion of the transaction, the insider now directly owns 153,544 shares of the company’s stock, valued at approximately $379,253.68. The trade was a 29.48 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Harith Rajagopalan sold 96,517 shares of the stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $2.47, for a total transaction of $238,396.99. Following the sale, the chief executive officer now owns 491,329 shares in the company, valued at approximately $1,213,582.63. The trade was a 16.42 % decrease in their position. The disclosure for this sale can be found here.

Fractyl Health Trading Down 4.2 %

NASDAQ:GUTS opened at $1.82 on Friday. The firm has a market capitalization of $87.54 million and a P/E ratio of -0.15. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.58 and a quick ratio of 5.57. Fractyl Health, Inc. has a one year low of $1.74 and a one year high of $14.50. The company’s 50-day simple moving average is $2.38 and its 200 day simple moving average is $3.23.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. The company had revenue of $0.01 million during the quarter. As a group, analysts forecast that Fractyl Health, Inc. will post -1.66 EPS for the current fiscal year.

Fractyl Health Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.